News Bio-Techne Corporation

Equities

TECH

US09073M1045

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 12:08:15 2026-04-15 EDT			5-day change	1st Jan Change
58.95 ^USD	+0.49%		+6.95%	+0.40%

04-13	TD Cowen Adjusts Price Target on Bio-Techne to $65 From $80, Maintains Buy Rating	MT
04-06	Evercore ISI Adjusts Price Target on Bio-Techne to $54 From $68, Maintains In Line Rating	MT

All News

04-14	Bio-Techne to Host Conference Call on May 6, 2026, to Announce Third Quarter Fiscal 2026 Financial Results	PR
04-13	TD Cowen Adjusts Price Target on Bio-Techne to $65 From $80, Maintains Buy Rating	MT
04-06	Evercore ISI Adjusts Price Target on Bio-Techne to $54 From $68, Maintains In Line Rating	MT
03-26	Bio-Techne Advances Spatial Biology with Modular Expansion of COMET Suite	AQ
03-25	Bio-Techne Corporation Expands Comet Solution Portfolio with Addition of Spyre Focus Panels and Spyre Amplification Kits	CI
03-25	Bio-Techne Advances Spatial Biology with Modular Expansion of COMET™ Suite	PR
03-10	Bio-Techne Corporation Presents at Leerink Global Healthcare Conference 2026, Mar-10-2026 08:40 AM
03-03	Bio-Techne Corporation Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 11:10 AM
02-24	Bio-Techne to Present at Upcoming Investor Conferences	PR
02-17	Cleo Diagnostics Selects Bio-Techne's Platform as Immunoassay Instrument for Ovarian Cancer Blood Test; Shares Jump 3%	MT
02-16	Bio-Techne's Ella Platform Achieves Ce-Ivd Marking Expanding Access to Rapid, Cartridge-Based Immunoassays for European Clinical Laboratories	CI
02-16	Bio-Techne Corp's Ella platform receives CE-IVD marking, available for sale in EU	RE
02-16	Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge‑Based Immunoassays for European Clinical Laboratories	PR
02-12		FA
02-11	Bio-Techne announces changes to its leadership team	RE
02-11	Bio-Techne Corporation Announces Executive Changes, Effective March 1, 2026	CI
02-11	Bio-Techne Announces Changes to its Leadership Team	PR
02-05	UBS Adjusts Price Target on Bio-Techne to $79 From $70, Maintains Buy Rating	MT
02-05	TD Cowen Adjusts Price Target on Bio-Techne to $80 From $70, Maintains Buy Rating	MT
02-05	Stifel Nicolaus Adjusts Bio-Techne PT to $65 From $60, Maintains Hold Rating	MT
02-05	Baird Adjusts Price Target on Bio-Techne to $70 From $61, Maintains Neutral Rating	MT
02-05	Wells Fargo Adjusts Bio-Techne PT to $76 From $70, Maintains Overweight Rating	MT
02-05	Evercore ISI Adjusts Price Target on Bio-Techne to $68 From $62, Maintains In Line Rating	MT
02-05	Leerink Partners Adjusts Price Target on Bio-Techne to $80 From $75, Maintains Outperform Rating	MT
02-04	Tranche Update on Bio-Techne Corporation's Equity Buyback Plan announced on May 6, 2025.	CI